Introduction/Overview
3-Epibetulinic acid, also known as 3-Epibetulinic acid, is a naturally occurring pentacyclic triterpenoid compound with a CAS number of 38736-77-5. As the C-3 isomer of Betulinic acid, it is widely present in various plants, especially in the Betulinic genus. For a long time, lupine triterpenoids, represented by betulinic acid, have attracted much attention due to their wide range of biological activities, including anti-inflammatory, antiviral, antimalarial, and most prominent anti-tumor activities. Betulinic acid, as its structural analogue, has gradually emerged from the "halo" of betulinic acid in recent years and become an emerging hotspot in the pharmacological research of natural products. Research has shown that betulinic acid exhibits significant anti-tumor potential, involving multiple pathways such as inducing cell apoptosis, inhibiting cell proliferation, invasion, and metastasis. It exerts its effects by acting on key targets such as MCL1, BCL2, STAT3, MMP2, TOP1, HIF1A, TOP2A, MAPK1, ESR1, CYP19A1, etc. Compared to some traditional chemotherapy drugs, it has the potential advantage of high selectivity and lower toxicity to normal cells. However, its poor solubility and bioavailability are the main bottlenecks restricting its translation into clinical applications. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, molecular mechanisms of action, pharmacological evaluation, and clinical application prospects of betulinic acid, in order to provide comprehensive scientific references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
Betulinic acid belongs to the lupine type pentacyclic triterpenoid compound, with a molecular formula of C30H48O3 and a molecular weight of 456.7110. Its core structure consists of five rings (A/B/C/D/E), and the only difference from betulinic acid is the stereochemistry of the C-3 hydroxyl group. The C-3 hydroxyl group of betulinic acid is in the β - configuration (straight bond), while the C-3 hydroxyl group of betulinic acid is in the α - configuration (flat bond). This slight stereochemical difference may significantly affect its interaction with biological targets, physicochemical properties, and ultimate biological activity.
From the analysis of physical and chemical properties, betulinic acid exhibits typical lipophilic characteristics. The calculated lipid water partition coefficient (LogP) is 6.2969, indicating its high hydrophobicity. The topological polar surface area (TPSA) is 57.53 Å ², which is relatively small. These parameters collectively determine its extremely low water solubility, with a literature reported value of approximately 0.0020 mg/mL, which poses the primary challenge for its formulation development. In pharmacokinetic predictions, the ability of the compound to cross the blood-brain barrier was evaluated as' low ', suggesting that it may not be suitable for the treatment of primary or metastatic central nervous system tumors, but may also reduce the risk of potential central nervous system side effects. In the early safety warning indicators, the predicted risk of hERG channel inhibition is "no", indicating a low potential risk of arrhythmia. The Ames test predicted a value of 0.0, indicating that it may not have direct genetic toxicity. These preliminary pharmacological parameters provide a key starting point for its subsequent structural optimization and dosage form improvement.
Plant sources and extraction methods
Betulinic acid is widely distributed in nature and mainly coexists with betulinic acid in various plants. Its most abundant source is the bark of birch plants such as Betula platyphylla and Betula pendula. In addition, it has also been detected in the leaves of Eriobortya japonica in the Rosaceae family, Phyllanthus plants in the Euphorbiaceae family, and Pterocarya stenoptera plants in the Walnut family. In plants, it often exists in the form of free acids or glycosides.
The extraction and separation method follows the conventional process of natural triterpenoids. Firstly, plant materials (such as birch bark) are dried and crushed, and extracted using lipophilic organic solvents. Common solvents include methanol, ethanol, chloroform, or mixed solvents of different proportions (such as chloroform methanol). After concentration, the crude extract is separated and purified using various chromatographic techniques, such as silica gel column chromatography, reverse phase column chromatography (RP-18), and high performance liquid chromatography (HPLC). Due to the extremely similar structure and polarity between betulinic acid and betulinic acid, separation is difficult and often requires the use of preparative HPLC or repeated column chromatography, as well as tracking and monitoring using thin layer chromatography (TLC) or liquid chromatography-mass spectrometry (LC-MS). In recent years, some green extraction techniques such as ultrasound assisted extraction and microwave-assisted extraction have also been applied to improve extraction efficiency. In addition, the semi synthetic transformation of abundant precursors such as betulinic acid is also a reliable chemical pathway to obtain betulinic acid.
Pharmacological activity research
The most notable pharmacological activity of Betulinic Acid is its extensive anti-tumor effects. A large number of in vitro studies have confirmed that it has significant proliferation inhibition and cytotoxicity effects on a variety of human tumor cell lines, including melanoma, breast cancer, lung cancer, colon cancer, prostate cancer, ovarian cancer, neuroblastoma and leukemia cells. Its activity intensity is usually dependent on concentration and time. It is worth noting that some studies have shown that the inhibitory activity of betulinic acid on certain cancer cells is superior to its isomer betulinic acid, highlighting the importance of the C-3 configuration.
Its anti-tumor effect is characterized by multiple pathways and links:
1. Inducing cell apoptosis This is one of the core functions of betulinic acid. It can directly induce apoptosis of the mitochondrial pathway, leading to a decrease in mitochondrial membrane potential, release of cytochrome c, and activation of the caspase cascade reaction.
2. Inhibit cell proliferation By interfering with the cell cycle progression, cells are blocked at specific checkpoints (such as G0/G1 phase or G2/M phase), thereby inhibiting the unlimited proliferation of tumor cells.
3. Anti invasion and anti metastasis Betulinic acid can significantly inhibit the migration and invasion ability of tumor cells, which is closely related to its downregulation of the expression and activity of matrix metalloproteinases (such as MMP2).
4. Angiogenesis inhibition By inhibiting the expression of hypoxia inducible factor HIF1A and its downstream vascular endothelial growth factor (VEGF), it interferes with the formation of tumor neovascularization and cuts off the nutritional supply to the tumor.
5. Other activities In addition to anti-tumor effects, studies also suggest that betulinic acid may have anti-inflammatory and antiviral (such as anti HIV) activities, but research in these areas is still in the preliminary stage, and its strength and mechanism need further clarification.
Mechanism of action and molecular targets
The anti-tumor effect of betulinic acid is not achieved through a single target, but through a complex signaling network, and its molecular mechanism research has delved into multiple key target proteins and pathways. According to the provided target information, its mechanism of action can be summarized as follows:
-
Regulating apoptosis balance (targeting MCL1, BCL2)MCL1 and BCL2 are important anti apoptotic Bcl-2 family proteins. Betulinic acid can downregulate the expression or interfere with the function of these proteins, thereby relieving their inhibition of pro apoptotic proteins such as Bax and Bak, promoting increased mitochondrial outer membrane permeability, and initiating the intrinsic apoptotic pathway.
-
Inhibition of survival and proliferation signals (targeting STAT3, MAPK1)STAT3 is a key transcription factor, and its sustained activation is closely related to tumor occurrence and development. Betulinic acid can inhibit the phosphorylation activation of STAT3 and suppress the transcription of downstream pro survival and proliferation genes such as Cyclin D1 and Bcl xL. MAPK1 (ERK2) is a core component of the MAPK/ERK pathway, which regulates cell growth and differentiation. Inhibiting MAPK1 signaling helps to suppress abnormal proliferation of tumor cells.
-
Interference with DNA metabolism and repair (targeting TOP1 and TOP2A)Topoisomerase I (TOP1) and II α (TOP2A) are key enzymes that regulate DNA topology and are targets of many chemotherapy drugs. Research has shown that betulinic acid may trigger cell death by inhibiting the activity of these enzymes, leading to irreparable damage during DNA replication and transcription processes.
-
Inhibition of invasion, metastasis, and angiogenesis (targeting MMP2 and HIF1A)Matrix metalloproteinase-2 (MMP2) can degrade extracellular matrix and is an important mediator of tumor invasion and metastasis. Betulinic acid reduces the invasive ability of tumor cells by downregulating the expression of MMP2. Hypoxia inducible factor-1 alpha (HIF1A) is a core regulatory factor for cells to adapt to hypoxic environments, regulating numerous pro angiogenic genes including VEGF. Inhibition of HIF1A activity is an important mechanism by which betulinic acid inhibits angiogenesis.
-
Intervention in hormone related pathways (targeting ESR1, CYP19A1)Estrogen receptor alpha (ESR1) and aromatase (CYP19A1) are important targets for hormone dependent breast cancer treatment. Preliminary research suggests that betulinic acid may act as an estrogen receptor modulator or aromatase inhibitor, interfering with the estrogen signaling pathway and thereby inhibiting the growth of hormone dependent tumors.
In summary, betulinic acid forms a powerful anti-tumor effect network through multi-target and multi pathway synergistic effects, which also provides potential advantages for overcoming the single target drug resistance of tumor cells.
Evaluation of drug properties and pharmacokinetics
Although betulinic acid exhibits excellent biological activity in vitro, its pharmacological properties, especially pharmacokinetic properties, are the main obstacles to its conversion into drugs.
Absorption, distribution, metabolism, excretion (ADME)Due to its extremely high LogP value and low water solubility, the oral bioavailability of Betulinic Acid is expected to be very poor. Its dissolution and absorption in the gastrointestinal tract are the rate limiting steps. Animal pharmacokinetic studies (mostly based on its analog betulinic acid) have shown that this type of compound is slowly and incompletely absorbed after oral administration, with low blood drug concentrations. In terms of distribution, its lipophilicity makes it easy to accumulate in adipose tissue, but its low blood-brain barrier permeability limits its application in central nervous system tumors. In terms of metabolism, triterpenoids mainly undergo liver phase I metabolism (such as CYP450 enzyme catalyzed hydroxylation) and phase II binding reactions (such as glucuronidation). The main pathways of excretion may be through bile and feces.
Formulation strategy To improve its water solubility and bioavailability, researchers have attempted various formulation strategies
* Prodrug design Esterify or amidate carboxyl or hydroxyl groups, or connect hydrophilic groups, and release the original drug after hydrolysis in vivo.
* Nano delivery system This is currently the most active research field. Including polymer nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, liposomes, micelles, etc. These nanosystems can effectively solubilize drugs, improve their stability, and achieve tumor targeted delivery by enhancing permeation and retention (EPR) effects, reducing systemic toxicity.
* Eutectic/co amorphous Form eutectic or amorphous complexes with suitable co morphs to increase dissolution rate.
* Cyclodextrin inclusion Using the cavity of cyclodextrin for encapsulation to increase the apparent solubility of drugs.
Preliminary evaluation of safety Based on existing data, Betulinic acid has no significant inhibition on hERG channels, and the Ames test predicts a negative result, indicating a low risk of cardiac and genetic toxicity. However, comprehensive preclinical safety evaluations (such as acute toxicity, chronic toxicity, reproductive toxicity, etc.) still need to be systematically carried out.
Clinical application prospects and prospects
Betulinic acid, as a natural lead compound with multi-target anti-tumor activity, has broad clinical application prospects, but the road ahead is long and full of challenges.
Potential application directions：
1. Antitumor therapy This is the most core application area. Given its activity against various solid tumors and hematological malignancies, as well as its potential to overcome drug resistance, it is expected to be developed as a novel broad-spectrum anti-tumor drug, particularly suitable for tumor types that are insensitive or resistant to traditional chemotherapy. Combining with existing chemotherapy drugs or targeted drugs may result in synergistic effects, reducing their respective dosages and toxic side effects.
2. Cancer chemoprevention Its anti-inflammatory, antioxidant, and early cancer suppression properties make it potentially valuable in the field of cancer prevention and healthcare.
3. other diseases: Further exploration of its antiviral and anti-inflammatory activities may expand its application in the treatment of infectious diseases and chronic inflammatory diseases.
Challenges faced and future research directions：
1. Solubility and delivery How to effectively solve the problems of water solubility and bioavailability through advanced formulation technology or reasonable structural modification is the first step towards clinical practice.
2. Deep analysis of mechanism At present, the understanding of its target of action is still mostly based on correlation studies, and more biophysical and structural biology evidence (such as eutectic structure) is needed to clarify its direct target of action and precise binding mode.
3. In vivo efficacy and safety verification We need to design rigorous in vivo pharmacological experiments in various human tumor xenograft (PDX) models or immune healthy models, and systematically complete preclinical safety evaluations that meet the requirements of new drug application.
4. structural optimization Using betulinic acid as the parent nucleus, a systematic structure-activity relationship study and structural optimization were conducted with the aim of enhancing activity, improving pharmacokinetic properties, and reducing potential toxicity.
5. Clinical translational research After completing sufficient preclinical research, gradually advance Phase I and Phase II clinical trials to explore their safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy in humans.
Conclusion
3-Epibetulinic acid, as a plant derived lupine triterpenoid compound, has become a promising new star in the field of natural anti-tumor drug development due to its multi-target, multi pathway anti-tumor mechanism and high selectivity. From regulating apoptosis (MCL1, BCL2), inhibiting survival signals (STAT3, MAPK1), interfering with DNA metabolism (TOP1, TOP2A), inhibiting metastatic angiogenesis (MMP2, HIF1A), and even intervening in hormone pathways (ESR1, CYP19A1), its extensive molecular target interaction network provides a solid scientific basis for its powerful biological activity. However, its inherent physical and chemical properties, especially its extremely low water solubility and bioavailability, create a gap between laboratory research and clinical applications. Future research should focus on utilizing modern medicinal chemistry and pharmaceutical methods, such as nano targeted delivery systems and prodrug strategies, to break through their delivery bottlenecks; At the same time, deepen its molecular mechanism research, clarify direct targets, and carry out systematic preclinical development. With the gradual resolution of these scientific issues, betulinic acid is expected to be successfully transformed from a promising natural lead compound into an innovative drug for clinical treatment, providing new treatment options for cancer patients.
